15 Participants Needed

Umbilical Cord Patch for Spina Bifida

CD
SF
Overseen ByStephen Fletcher, DO
Age: < 18
Sex: Any
Trial Phase: Academic
Sponsor: The University of Texas Health Science Center, Houston
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores a new method to assist babies born with spina bifida, a condition where the spine doesn't form properly. Researchers are using an Autologous Human Umbilical Cord Tissue Patch, made from the baby's own umbilical cord, to determine if it can more effectively close the spinal defect, create additional space in the spinal canal, and reduce inflammation compared to previous methods. Babies diagnosed with spina bifida before birth and meeting specific health criteria may be suitable candidates for this trial. As an unphased study, this trial provides a unique opportunity to contribute to groundbreaking research that could enhance future treatment options for spina bifida.

Will I have to stop taking my current medications?

The trial does not specify if participants must stop taking their current medications, but it excludes those who have used steroid therapy during pregnancy, except for lung maturity. It also excludes those treated with investigational drugs that could affect health outcomes.

What prior data suggests that this umbilical cord patch is safe for spina bifida repair?

Research has shown that using a patch made from a patient's own umbilical cord tissue is generally safe. Studies have found that patients usually tolerate this type of patch well, with no serious side effects. Past studies reported no unexpected health problems, suggesting that these patches might be a safe option for treating conditions like spina bifida, where the spine does not develop properly. It is important to consult a healthcare provider to understand the potential risks and benefits for each specific situation.

Why are researchers excited about this trial?

Unlike the standard surgical treatments for spina bifida, which often involve closing the defect with synthetic materials or skin grafts, the umbilical cord patch is derived from the patient's own umbilical cord tissue. This unique approach offers a personalized treatment, which may reduce the risk of rejection and infection. Researchers are excited because this method could promote better healing and integration with the body, potentially leading to improved outcomes for babies born with spina bifida.

What evidence suggests that the autologous umbilical cord patch is effective for spina bifida?

Research has shown that using a patch made from a baby's own umbilical cord tissue for treating spina bifida looks promising. In this trial, participants will receive an autologous umbilical cord patch. Previous studies found that this type of patch can effectively close the openings in the spine. Since the patch is made from the baby's own tissue, it might lower the risk of rejection or cause less swelling and irritation compared to other materials. Early findings suggest that it can help enlarge the spinal canal, benefiting the spinal cord's function. While more research is needed, these results offer hope for better outcomes in treating spina bifida.

Who Is on the Research Team?

SF

Stephen Fletcher, DO

Principal Investigator

The University of Texas Health Science Center, Houston

Are You a Good Fit for This Trial?

This trial is for individuals with open neural tube defects like Spina Bifida or Tethered Cord Syndrome. It's specifically looking at those who can provide their own umbilical cord tissue for the procedure.

Inclusion Criteria

Resident of the United States
Provision of signed and dated informed consent form
Stated willingness by legally authorized representative (LAR) to comply with all study procedures and availability for the duration of the study
See 1 more

Exclusion Criteria

Febrile or other acute illness of the neonate at time of delivery
My baby has a major birth defect not related to spina bifida that could affect surgery safety.
Vaginal delivery
See 8 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive an autologous umbilical cord patch for dural closure to repair open neural tube defects

Immediate postnatal period

Follow-up

Participants are monitored for successful defect closure, spinal canal capacity, and inflammatory response

6 months

What Are the Treatments Tested in This Trial?

Interventions

  • Autologous Human Umbilical Cord Tissue Patch
Trial Overview The study tests using a patient's own umbilical cord tissue as a patch to repair an open neural tube defect, aiming to see if it leads to better outcomes compared to past methods.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: Autologous umbilical cord patchExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

The University of Texas Health Science Center, Houston

Lead Sponsor

Trials
974
Recruited
361,000+

Published Research Related to This Trial

The study found that using cryopreserved human umbilical cord (HUC) patches for in utero repair of spina bifida resulted in significantly better spinal cord function in lambs compared to acellular dermal matrix (ADM) patches, as measured by the Texas Spinal Cord Injury Scale.
Histological analysis showed that the HUC group had lower levels of inflammation and fewer activated astrocytes compared to the ADM group, indicating that HUC patches may provide a more effective and safer option for reducing inflammation and preserving neurological function during spina bifida repair.
Allografts for Skin Closure during In Utero Spina Bifida Repair in a Sheep Model.Mann, LK., Won, JH., Patel, R., et al.[2021]
In a study involving pregnant ewes, using a cryopreserved human umbilical cord patch to repair surgically created spina bifida significantly improved neurological outcomes compared to unrepaired cases, as indicated by higher Texas Spinal Cord Injury Scale scores and partial bladder control.
Lambs that received the HUC patch showed complete healing of skin defects and better overall survival rates, suggesting that this intervention could be a promising approach for treating spina bifida in utero.
Neurological Outcomes after Human Umbilical Cord Patch for In Utero Spina Bifida Repair in a Sheep Model.Papanna, R., Mann, LK., Snowise, S., et al.[2022]
In a study comparing cryopreserved human umbilical cord (HUC) patches to acellular dermal matrix (ADM) patches for repairing in utero spina bifida defects in rats, the HUC patches resulted in lower inflammation and apoptosis, indicating a safer and more effective option for repair.
The HUC patches also promoted better cellular organization and growth, suggesting they could improve spinal cord function and reduce complications like tethering compared to ADM patches, making them a promising material for future spinal surgeries.
Cryopreserved human umbilical cord versus acellular dermal matrix patches for in utero fetal spina bifida repair in a pregnant rat model.Mann, LK., Won, JH., Trenton, NJ., et al.[2020]

Citations

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security